Omnicuris Logo
Dr. Dharminder Nagar Joins FICCI as Healthcare Co-Chair

Dr. Dharminder Nagar Joins FICCI as Healthcare Co-Chair

Read More
Full Text
3 months ago
The FICCI Healthcare Committee recently announced the appointment of Dr. Dharminder Nagar as its new Co-Chair. Dr. Nagar currently serves as the Managing Director of Paras Health. He brings nearly two decades of leadership experience to this national platform. Consequently, his appointment marks a significant step forward for healthcare policy and innovation in India. Industry leaders believe his expertise will drive impactful reforms across the sector.

Strategic Goals for FICCI Healthcare Committee



In his new position, Dr. Nagar aims to drive several critical initiatives. Specifically, he plans to focus on advancing digital and AI-enabled healthcare delivery across the country. Additionally, he intends to strengthen healthcare infrastructure in Tier II and Tier III cities. Furthermore, building workforce capacity remains a top priority for the committee under his leadership. He also supports policy frameworks that improve patient safety and affordability for all citizens. Therefore, he looks forward to collaborating with stakeholders to build inclusive healthcare systems.

Dr. Nagar has over 19 years of leadership experience. During this time, he was instrumental in expanding the footprint of Paras Health. The organization now operates eight hospitals across regions like Gurugram, Panchkula, Patna, and Srinagar. His academic background is equally distinguished. For instance, he completed an Executive Management Programme from Harvard Business School. Moreover, he holds degrees from Singularity University, BITS, and Imperial College London. His deep understanding of clinical technology will likely strengthen the committee’s upcoming initiatives.

Frequently Asked Questions


Q1: Who is Dr. Dharminder Nagar?


Dr. Nagar is the Managing Director of Paras Health and the newly appointed Co-Chair of the FICCI Healthcare Committee.


Q2: What are the main focus areas for the new Co-Chair?


His primary focus areas include AI-enabled healthcare delivery, improving infrastructure in smaller cities, and enhancing patient safety policies.


Q3: How many hospitals does Paras Health currently operate?


Under Dr. Nagar's leadership, Paras Health has expanded to include eight hospitals across northern and eastern India.



Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.



References



  1. Dr Dharminder Nagar appointed Co-Chair of FICCI Healthcare Committee - ETHealthworld

  2. FICCI - Health Services Division Overview

  3. Paras Health - Corporate Leadership Profiles

Login to continue

More from MedShots Daily

Dr. Dharminder Nagar Joins FICCI as Healthcare Co-Chair
Dr. Dharminder Nagar Joins FICCI as Healthcare Co-Chair

Dr. Dharminder Nagar, MD of Paras Health, is the new Co-Chair of the FICCI Healthcare Committee, focusing on digital health and infrastructure in Tier II/II...

3 months ago

Read More
Full Text
Vascular Markers and Muscle Health: The Impact of Abdominal Aortic Calcification
Vascular Markers and Muscle Health: The Impact of Abdominal Aortic Calcification

UK Biobank findings reveal that abdominal aortic calcification is independently associated with poor muscle composition and a higher risk of incident falls....

Today

Read More
Full Text
Preoperative Predictors of Blood Transfusion in Placenta Accreta Spectrum
Preoperative Predictors of Blood Transfusion in Placenta Accreta Spectrum

A study identifies placenta previa and ultrasound suspicion as major predictors for intraoperative blood transfusion in placenta accreta spectrum management...

Today

Read More
Full Text
Procizumab: A Novel Humanized Antibody for Neutralizing Circulating DPP3 in Shock
Procizumab: A Novel Humanized Antibody for Neutralizing Circulating DPP3 in Shock

Procizumab is a humanized antibody that neutralizes circulating DPP3, a biological driver of shock, by preventing angiotensin II degradation....

Today

Read More
Full Text
Medtronic Acquires SPR Therapeutics for $650 Million
Medtronic Acquires SPR Therapeutics for $650 Million

Medtronic has announced its plans to acquire SPR Therapeutics for $650 million, expanding its non-opioid, minimally invasive chronic pain treatments....

Today

Read More
Full Text
Palopegteriparatide Sustains Renal Function Improvement in Chronic Hypoparathyroidism: 2-Year PaTHway Results
Palopegteriparatide Sustains Renal Function Improvement in Chronic Hypoparathyroidism: 2-Year PaTHway Results

Two-year results from the PaTHway trial show that palopegteriparatide improves eGFR and reduces reliance on conventional therapy in chronic hypoparathyroidi...

Today

Read More
Full Text
Showing Page 1 of 1(5 items total)
Go to Page

"Wherever the art of Medicine is loved, there is also a love of Humanity."

— Hippocrates

made with❤️byOmnicuris